Document is current
Any future updates will be listed below
-
Authors
Zinzani, Pier Luigi
Muñoz, Javier
Trotman, Judith
- License Information
-
More Information
Article History
Received: 6 June 2024
Accepted: 2 August 2024
First Online: 22 August 2024
Declarations
:
: Not applicable.
: Not applicable.
: PLZ: Honoraria: BeiGene, Bristol Myers Squibb, Gilead, Incyte, Kyowa Kirin, MSD, Novartis, Roche, and Takeda. JT: Research funding: BeiGene, Janssen, Pharmacyclics, Roche, Celgene/Bristol Myers Squibb, and Selectar; Advisory board: BeiGene. JM: Consulting/advisory role: Pharmacyclics/AbbVie, Bayer, Gilead/Kite, BeiGene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech/Roche, ADC Therapeutics, Epizyme, BeiGene, Novartis, MorphoSys/Incyte, MEI, TG Therapeutics, AstraZeneca, Eli Lilly; Research funding: Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, BeiGene; Honoraria: Targeted Oncology, OncView, Curio, and Physicians’ Education Resource.
